Glucagon may lose its ability to raise blood glucose or may produce hypoglycemia in patients taking indomethacin. Monitor blood glucose levels during glucagon treatment.
Source: NLP:glucagon
Glucagon Interactions
Brand names: Glucagon
Antihypoglycemic Agent · Gastrointestinal Motility Inhibitor
Route: Intramuscular, Intravenous
Contraindications
4 CONTRAINDICATIONS Glucagon for injection is contraindicated in patients with: Pheochromocytoma because of the risk of substantial increase in blood pressure [see Warnings and Precautions ( 5.1 )] Insulinoma because of the risk of hypoglycemia [see Warnings and Precautions ( 5.2 )] Known hypersensitivity to glucagon or any of the excipients in glucagon for injection. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension [see Warnings and Precautions ( 5.3 )] Glucagonoma when used as a diagnostic aid because of the risk of hypoglycemia [see Warnings and Precautions ( 5.8 )] Pheochromocytoma ( 4 ) Insulinoma ( 4 ) Known hypersensitivity to glucagon or to any of the excipients ( 4 ) Glucagonoma when used as a diagnostic aid ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary Available data from case reports and a small number of observational studies with glucagon use in pregnant women over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Multiple small studies have demonstrated a lack of transfer of pancreatic glucagon across the human placental barrier during early gestation. In a rat reproduction study, no embryofetal toxicity was observed with glucagon administered by injection during the period of organogenesis at doses representing up to 40 times the human dose, based on body surface area (mg/m 2 ) (see Data) . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. Data Animal Data In pregnant rats given animal sourced glucagon twice-daily by injection at doses up to 2 mg/kg (up to 40 times the human dose based on body surface area extrapolation, mg/m 2 ) during the period of organogenesis, there was no evidence of increased malformations or embryofetal lethality.
14 interactions on record
Glucagon + GlimepirideModerate
May reduce glucose-lowering effect of glimepiride, leading to worsening glycemic control.
Source: NLP:glimepiride
Glucagon + GlipizideModerate
May reduce the glucose-lowering effect of glipizide, leading to worsening glycemic control. Monitor closely.
Source: NLP:glipizide
May decrease the blood glucose lowering effect. Dose adjustment and increased glucose monitoring required.
Source: NLP:insulin aspart
Glucagon + Insulin Aspart-SzjjModerate
May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin aspart-szjj
Glucagon + Insulin DegludecModerate
May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Source: NLP:insulin degludec
Glucagon + Insulin GlargineModerate
May decrease blood glucose lowering effect of insulin glargine; dosage increases and increased glucose monitoring may be required.
Source: NLP:insulin glargine
Glucagon + Insulin GlulisineModerate
May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin glulisine
Glucagon + Insulin HumanModerate
Insulin acts antagonistically to glucagon. Monitor blood glucose when glucagon is used as a diagnostic aid in patients receiving insulin.
Source: NLP:glucagon
Glucagon + Insulin LisproModerate
May decrease blood glucose lowering effect; dose adjustment and increased glucose monitoring required.
Source: NLP:insulin lispro
Glucagon + Insulin Lispro-AabcModerate
May decrease blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.
Source: NLP:insulin lispro-aabc
Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given glucagon. The increase may require therapy in patients with coronary artery disease.
Source: NLP:glucagon
Glucagon + RepaglinideModerate
May decrease blood glucose lowering effect of repaglinide. Dose increases and increased glucose monitoring may be required.
Source: NLP:repaglinide
Glucagon + WarfarinModerate
Glucagon may increase the anticoagulant effect of warfarin. Monitor patients for unusual bruising or bleeding; warfarin dosage adjustments may be required.
Source: NLP:glucagon